- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00856336
Phase I Safety Study of DMXAA in Refractory Tumors (DART)
5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) in the Treatment of Refractory Tumors: A Phase I Multicentre Doubleblind Randomized Six-Way Intrapatient Dose-Ranging Crossover Safety Study.
Study Overview
Detailed Description
This was a multi-centre randomized, double blind study to further characterize the effect of DMXAA on QTc interval, ophthalmic safety and pharmacodynamic effects on tumour blood flow.
Patients with refractory tumors were to each undergo six doses of treatment at weekly intervals, receiving each of six doses of DMXAA (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Evidence of cancer, by histopathology or cytology, which was not amenable to any standard therapy or was refractory to conventional therapy
- Age ≥ 18 years
- Life expectancy of at least 12 weeks
- WHO performance status of 0-2
Hematological and biochemical indices at the start of treatment:
- Hemoglobin at least 9 g/dl
- Leukocyte count at least 3.0 x 109/l
- Neutrophils at least 1.5 x 109/l
- Platelets at least 100 x 109/l
- Serum Creatinine not higher than140 μmol/l
- Liver function tests (ALT, AST, ALK PHOS) no higher than thrice the upper limit of the reference range, if no demonstrable liver metastases or no more than 5 x upper limit of the normal range in the presence of liver or bone metastases
- Absolute QTc interval values of less than 470 ms in females and less than 450 ms in males as assessed by the Investigator
- Presence of a lesion which was amenable to dynamic MRI
- Written informed consent and the ability of the patient to co-operate with treatment and follow up
Exclusion Criteria:
- Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks prior to treatment
- Pregnant or lactating women were excluded
- Patients who were poor medical risks because of non-malignant systemic disease, as well as those with active uncontrolled infection
- Current malignancies at other sites
- Significant history of recreational drug abuse
- Glucocorticosteroids in doses exceeding those required for physiological replacement within the previous 2 weeks
- Skin lesions that may prevent long-term ECG acquisition
- Body mass index above 30 kg/m2
- Patients who were taking certain medications
- Patients with clinical evidence of brain metastases
Patients with certain cardiac conditions
- Advancing or unstable ischemic heart disease
- Pacing devices and/or implantable cardiovertor-defibrillator
- Significant cardiovascular disease or any unstable cardiovascular disease
- Non-sustained or sustained atrial and/or ventricular tachyarrhythmias
- Atrial fibrillation (including paroxysmal atrial fibrillation) or atrial flutter
- Bundle Branch Block, any stable intra-cardiac conduction abnormality with QRS complex > 120 ms, any unstable intra-cardiac conduction abnormality
- Sick sinus syndrome, or sinus pauses > 2 seconds
- Known atrial and/or ventricular ectopic beats > 10/hour
- Fixed second degree AV block, transient or fixed third degree AV block
- History of documented ventricular flutter, ventricular fibrillation, Torsade de Pointes tachycardia
- Patients who had previously received anthracyclines or other known cardiotoxic medication
- Women with breast implants as these may have interfered with the recording of the ECG
- Patients with severe electrolyte abnormalities and patients in whom transient electrolyte abnormalities may have been expected during any visit of the study
- Patients in whom concomitant neurotropic drug therapy was known to change or was likely to change during the course of the study, where such therapy was likely to affect the patients ERG measurement
- Ophthalmic conditions where in the opinion of the investigator they might affect the recording of the ERG
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To identify a range of doses for DMXAA where there was either no effect or an acceptably small effect on QTc
|
Secondary Outcome Measures
Outcome Measure |
---|
To investigate and describe the relationship between QTc prolongation, plasma levels of DMXAA and time from start of infusion.
|
To further investigate the safety profile of DMXAA
|
To further investigate the pharmacokinetic behaviour of DMXAA
|
To further characterise the ophthalmic effects of DMXAA
|
To document anti-tumour activity and/or clinical signs of efficacy in patients
|
To assess the effects of DMXAA on tumour blood flow using dynamic MRI
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark McKeage, The University of Auckland
- Principal Investigator: Michael Jameson, Waikato Hospital
- Principal Investigator: Mark Jeffery, Christchurch Hospital
Publications and helpful links
General Publications
- McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res. 2006 Mar 15;12(6):1776-84. doi: 10.1158/1078-0432.CCR-05-1939.
- Jameson MB, Sharp DM, Sissingh JI, Hogg CR, Thompson PI, McKeage MJ, Jeffery M, Waller S, Acton G, Green C, Baguley BC. Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials. Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2553-9. doi: 10.1167/iovs.08-2068. Epub 2009 Apr 22.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- DART
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Tumors
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedMalignant Tumors | Refractory TumorsFrance
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
University of Colorado, DenverUniversity of KentuckyCompletedRefractory Solid Tumors | Relapsed Solid TumorsUnited States
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
OncoMed Pharmaceuticals, Inc.CompletedRefractory Solid Tumors | Advanced Relapsed TumorsUnited States
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
Dr. Tapas K. Das GuptaCompletedRefractory Solid TumorsUnited States
-
M.D. Anderson Cancer CenterRecruitingRefractory Solid TumorsUnited States
-
PharmaEngineCompletedRefractory Solid TumorsTaiwan
Clinical Trials on DMXAA
-
Novartis PharmaceuticalsTerminated
-
Antisoma ResearchCompletedProstate CancerUnited States
-
Antisoma ResearchCompleted
-
Cancer Research UKCancer Society AucklandCompleted
-
Novartis PharmaceuticalsTerminated
-
Korean Pharmacoacupuncture InstituteUnknown
-
University of California, San FranciscoNovartis PharmaceuticalsWithdrawn